Supplementary Figure 1: CONSORT Flow Chart
1: Not available;
assessed at follow-up Assessed at End of Study: 20
Assessed at End of Study: 22
Assessed at Follow-Up: 21 Assessed at Follow-Up: 22
Withdrawn: 5 2: Study med non- compliance
1: Started part-time job 1: Abnormal lab
1: Abnormal EKG
Assessed at Mid-Treatment: 23 Entered 2-week Evaluation Phase: 79
Underwent randomization: 62 Completed 2-week Evaluation Phase: 66
Assessed at Mid-Treatment: 27
Withdrawn: 8
3: Patient withdrew consent 2: Refused to participate due to
perceived side effects 1: Clinical worsening 1:Withdrawn by board/care 1: Moved away
Withdrawn prior to exposure: 2 2: Loss of interest
Withdrawn: 2
1: Stopped taking study drug 1: Did not fit subject’s schedule
Withdrawn: 4
1: Refused to participate 1: Abnormal labs
1: Recent CBSST exposure
1: Substance use Withdrawn: 9
3: Lost contact
2: Refusal to participate 1: Unstable living situation 1: Loss of interest
1: Withdrawn by care- provider
1: Subject moved Excluded: 4
1: Did not meet SANS criteria
1: Low sodium level 2: Abnormal labs
Withdrawn: 2 1: Abnormal labs 1: Abnormal EKG Started CBSST: 29
Not enrolled: 4
1: Did not fit schedule 1: Abnormal labs 1: Substance abuse 1: Refusal to participate
Signed Consent: 83
Started CBSST: 31 Placebo: 31 Oxytocin: 31
